BioNeutra Announces Results of Annual General and Special Meeting of the Shareholders for Year Ended December 31, 2014

EDMONTON, Alberta, August 24, 2015 – BioNeutra Global Corporation (CSE: BGA) (“BioNeutra” or the “Company“) is pleased to report the results of the annual general and special meeting of the shareholders (the “Meeting”) for the financial year ending December 31, 2014 held on Wednesday, October 28, 2015 as scheduled.

At the Meeting, shareholders approved each of the following resolutions:

i. fixing the size of the Board of Directors at eight (8) members;

ii. re-electing Dr. Jianhua Zhu, Bill Smith, Lionel Eshleman, C.H. William (Bill) Cheung, and Huifen Zhang, and electing Honourable David Hancock, Q.C., LL.D (Hons), James Li, and Jiayu Guan as members of the Company’s Board of Directors to hold office until the date of the next annual meeting of the Company’s shareholders;

iii. appointing Collins Barrow LLP, Chartered Accountants, as the Company’s auditors for the ensuing year;

iv. approving the implementation of the Company’s Stock Option Plan on the terms described in Schedule B to the Management Information Circular; and

v. ratifying the Board of Directors’ resolution of September 1, 2015 to repeal the Company’s bylaws and replace them with the bylaws attached as Schedule C to the Management Information Circular.

Mr. Bill Smith, Chairman & Senior Vice President of BioNeutra Global Corporation, states, “We are very excited about the additions to BioNeutra’s Board of Directors. The three new members, combined with the five returning members, bring an excellent blend of skills to advise the Company effectively and work with management to successfully achieve the goals set forth. It is my hope that our Directors will bring forward new ideas to challenge management and the rest of the Board.”

About BioNeutra Global Corporation
BioNeutra is in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages, with a focus on oligosaccharides.

The Company’s lead product, VitaFiber™, is an advanced functional and health food ingredient scientifically made from natural agricultural products, is generally regarded as safe (GRAS) by the U.S. Food & Drug Administration, and is European Food Safety Authority and Health Canada approved. VitaFiber™ is naturally sweet and lower in calories than regular sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health.

The Company produces VitaFiber™ using its patented processes that naturally transforms starch molecules from agriculture cereal crops including corn, wheat, barley, potato, or tapioca into the functional health molecules of isomalto-oligosaccharide (IMO). The VitaFiber™ manufacturing process is based upon a natural enzymatic conversion of starch molecules without any chemical modification involved, making VitaFiber™ a natural food ingredient. VitaFiber™ is also non-GMO, vegan-friendly, gluten-free, Kosher and Halal certified and available as certified organic.

The Company’s customers include a mix of small and medium enterprises and a number of high-profile food manufacturers in Canada, the U.S., Europe, the United Kingdom, and Mexico. VitaFiber™ is also available for retail purchase across the globe through and other direct-to-consumer retailers.

Further information about BioNeutra is available on the Company’s website at, the SEDAR website at and on the CSE website at

For further information contact:

BioNeutra Global Corporation
Bill Smith, Chairman & Senior Vice President
T: (780) 466-1481 x 117

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.


9608 25 Avenue NW
Edmonton, Alberta T6N 1J4
Tel: 1.780.466.1481
Fax: 1.780.801.0036

©2019 BioNeutra